<DOC>
	<DOCNO>NCT02826252</DOCNO>
	<brief_summary>The aim study examine inhalation behavior patient enrolled German Ventavis patient support program Ventaplus patient switch Ventavis ( Iloprost ) 10 μg/mL Ventavis ( Iloprost ) 20 μg/mL formulation .</brief_summary>
	<brief_title>Examination Ventavis ( Iloprost ) Inhalation Behavior Using I-Neb AAD System Patients With Pulmonary Arterial Hypertension When Switching Iloprost Nebulizer Solution Inhalation From 10 μg/mL ( V10 ) 20 μg/mL ( V20 )</brief_title>
	<detailed_description>The VENTASWITCH study local , prospective retrospective , observational , case-crossover study . Data collect download I-Neb AAD ( Adaptive Aerosol Delivery ) System . Two data collection period plan : period one ; data collection last 3 month use Ventavis ( Iloprost ) 10 μg/mL ( V10 ) index date switch Ventavis ( Iloprost ) 20 μg/mL ( V20 ) ( retrospective part ) period two ; data collection 3 month use V20 index date ( prospective part ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>Patients age ≥18 year time signing informed consent . Patients , diagnose group 1 PAH . Patients must enrol German Ventavis patient support program Ventaplus . Patients either already switch V10 V20 therapy agree accord physician 's decision . Patients must V10 therapy least 2 week . Written informed consent must obtain . participation clinical interventional study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pulmonary Arterial Hypertension ( PAH )</keyword>
</DOC>